Clinical trials: Recurrent Solid Tumor
Squamous Cell Carcinoma of Head and Neck
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
The primary objective of this study was to estimate the response rate to ALKS 4230 in combination with pembrolizumab in patients with HNSCC who had previously received anti-PD-(L)1 therapy but who had not achieved a CR.
- Trial name
- NCT04144517
- Testing
- Nemvaleukin Alfa, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Mural Oncology, Inc
Metastasis, Locally Advanced Solid Tumor
Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients
XRD-0394 is a novel, potent, oral, small molecule dual inhibitor of ataxia telangiectasia mutated kinase (ATM) and deoxyribonucleic acid (DNA)-dependent protein kinase (DNA-PK) that has selectivity compared with other…
- Conditions
- Metastasis, Locally Advanced Solid Tumor, Recurrent Cancer
- Trial name
- NCT05002140
- Testing
- XRD-0394, Palliative radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- XRad Therapeutics Inc
Ovarian Cancer, Solid Tumors
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
This is a multi-center, randomized, open-label, phase 1/2 study of continuous weekly paclitaxel and escalating doses of intermittent or continuous OSI-906 in patients with recurrent/relapsed ovarian and other solid tumors.
- Trial name
- NCT00889382
- Testing
- OSI-906, Paclitaxel
- Where
- 46 sites in United States, Australia and 8 more
- Volunteers
- 152 people
- Sponsor
- Astellas Pharma Inc
Advanced or Recurrent Solid Tumors, Breast Neoplasms
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
This is a single-arm, open-label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of talazoparib in patients with advanced tumors with DNA-repair pathway deficiencies.
- Conditions
- Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma
- Trial name
- NCT01286987
- Testing
- Talazoparib
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 113 people
- Sponsor
- Pfizer
Cancer, Neoplasms
Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
IT141 is a novel nanoparticle formulation of SN-38, the active metabolite of irinotecan, and is intended to deliver more drug to the tumor with reduced toxicity on normal tissues.
- Conditions
- Cancer, Neoplasms, Tumors, Refractory Solid Tumors
- Trial name
- NCT03096340
- Testing
- IT-141
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Intezyne Technologies, Inc.
Advanced or Recurrent Solid Tumors
Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors
This study will assess the tolerability of combination therapy with ASA404 and docetaxel in Japanese patients with advanced or recurrent solid tumors.
- Trial name
- NCT01285453
- Testing
- vadimezan
- Where
- 2 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor, Adult, Solid Tumor
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms
- Trial name
- EVEREST-1 (NCT05736731)
- Testing
- A2B530, xT-Onco with HLA-LOH Assay
- Where
- 8 sites in United States
- Volunteers
- 160 people
- Sponsor
- A2 Biotherapeutics Inc.
Relapsed Malignant Solid Neoplasm
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced malignancies will be done to assess AUR107 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.
- Trial name
- NCT05865002
- Testing
- AUR107
- Where
- 37 sites in India
- Volunteers
- 50 people
- Sponsor
- Aurigene Discovery Technologies Limited
Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC)
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
This clinical trial is evaluating a drug called MDSY-2140 in participants with hematologic malignancies and advanced solid tumors.
- Conditions
- Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer Metastatic
- Trial name
- NCT07899632
- Testing
- MDSY-1240
- Volunteers
- 75 people
- Sponsor
- Medsyn Biopharma, LLC
Lymphoma, Small Intestine Cancer
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced or…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00049699
- Testing
- laromustine
- Where
- 3 sites in United States
- Sponsor
- Vion Pharmaceuticals
Solid Tumor, Triple Negative Breast Cancer
RX-5902 Treatment of Subjects With Triple Negative Breast Cancer
The purpose of this Phase 2 portion of the study is to use the dose and schedule of RX-5902 identified in the phase 1 to treat subjects with triple negative breast cancer.
- Trial name
- NCT02003092
- Testing
- RX-5902
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Rexahn Pharmaceuticals, Inc.
Adult Solid Tumor
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
This is a Phase 1/2, first-in-human, open label, multicenter study to assess safety and tolerability, antitumor activity, and immunogenic and pharmacodynamic effects of SQZ-eAPC-HPV as monotherapy and in combination with…
- Trial name
- NCT05357898
- Testing
- SQZ-eAPC-HPV, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- SQZ Biotechnologies
HER2-positive Advanced Solid Tumor
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
- Trial name
- NCT05150691
- Testing
- DB-1303/BNT323, Pertuzumab Injection, Ritonavir
- Where
- 102 sites in United States, Australia and 4 more
- Volunteers
- 796 people
- Sponsor
- DualityBio Inc.
Solid Tumor Cancers
To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors
To evaluate the safety and tolerability of the veliparib/TMZ combination in subjects with solid tumors.
- Trial name
- NCT01193140
- Testing
- veliparib, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Abbott
Cancer, Multiple Indications
Multiple Ascending Dose (MDX1105-01)
Collection of survival data, evaluation of PDL-1 expression in tumors, and evaluation of PD-L1 receptor occupancy in peripheral blood has been added.
- Trial name
- Anti-PDL1 (NCT00729664)
- Testing
- Anti-PDL-1 antibody
- Where
- 11 sites in United States
- Volunteers
- 281 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors, Recurrent Solid Tumors
ONO-4538 Phase I Study in Patients With Solid Tumor
The objective of this study is to investigate the safety, pharmacokinetics, pharmacology and efficacy of ONO-4538 administered to Korean patients with advanced or recurrent solid tumors who are refractory or intolerant to…
- Trial name
- NCT02261298
- Testing
- ONO-4538
- Where
- 5 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Relapsed Neuroblastoma, Refractory Neuroblastoma
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
This illustrative Phase 1/Phase 2 study tests allogeneic dual-target GD2/B7-H3 (CD276) CAR-NK cells in children and young adults with relapsed or refractory neuroblastoma.
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, High-Risk Neuroblastoma, Ganglioneuroblastoma
- Trial name
- DUAL-NK-NB (NCT07502287)
- Testing
- EB-DTNB-NK, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Recurrent Glioblastoma
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma
The purpose of this study is to see how effective cediranib is in treating a brain tumour called recurrent glioblastoma. Two drugs are being tested in this study.
- Trial name
- REGAL (NCT00777153)
- Testing
- Cediranib, Lomustine Chemotherapy
- Where
- 62 sites in United States, Australia and 8 more
- Volunteers
- 423 people
- Sponsor
- AstraZeneca
Relapsed or Refractory Lymphomas, Advanced Solid Tumor
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or…
- Trial name
- NCT06132503
- Testing
- LP-284
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Lantern Pharma Inc.
Solid Tumors
A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors
Phase 1, open-labeled, safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.
- Trial name
- NCT00674947
- Testing
- BIIB015
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Biogen